A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases

Inclusion Criteria: * Histologically or cytologically confirmed lung cancer or breast cancer at primary site * Patient with inoperable brain metastases * Female or male, ≥ 20 and \< 65 years of age * Karnofsky performance status (KPS) ≥ 70% * Life expectancy ≥ 12 weeks * Adequate organ function * Willing and able to provide a written informed consent Exclusion Criteria: * Female of childbearing potential\* who is pregnant/lactating or planning to be pregnant * Male whose partner is planning to be pregnant * Inability to swallow * Meningeal carcinomatosis * History of hypersensitivity to iodinated contrast media, temozolomide or any component of the study drugs * Prior use of temozolomide * Use of systemic chemotherapy within 2 weeks prior to the initiation of study treatment * Prior surgery, chemotherapy or radiotherapy for a brain neoplasm * Current use of valproic acid * Use of any investigational product within 4 weeks prior to the initiation of study treatment * Patient with any condition or disease which is considered not suitable for this study by investigator